Researchers confirm breast cancer regulator also found in prostate cancer

Researchers at Clarkson University in Potsdam, N.Y., led by Chemistry & Biomolecular Science Professor Costel C. Darie, in collaboration with researchers from Columbia University, have now found the binding partner of TDF, a pituitary hormone that had previously been shown to reduce cancer progression in breast cancer cells, in prostate cancer as well.

The study suggests that TDF may play a general role of inhibiting cancerous cells in both the breast and in the prostate.

"Finding the receptor for the TDF hormone in both the breast and prostate will allow us to design treatments targeting both cancer types," said Darie.

Darie's group has led in the search for a cellular receptor in cancer cells that might bind TDF and inhibit tumor growth. A receptor, labeled TDF-R, was found exclusively in the prostate and breast, but not in other , suggesting that this factor is specific to these cancer types.

The results of the research will be reported in an upcoming issue of a journal published by the Federation of European Biochemical Societies (FEBS).

Most of the research work was performed by Izabela Sokolowska, a Ph.D. student in Darie's lab.

The work was supported in part by the U.S. Army Research Laboratory's Army Research Office (ARO) through the Defense University Research Instrumentation Program (DURIP grant #W911NF-11-1-0304) and the Keep A Breast Foundation (KEABF-375-35054).

According to the American Cancer Society about 241,740 new cases of prostate cancer will be diagnosed in 2012, approximately 28,170 men will die of prostate cancer and approximately one man in six will be diagnosed with in his life.

add to favorites email to friend print save as pdf

Related Stories

Breast cancer type linked to paternal cancer

Nov 28, 2011

The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Study identifies new prostate cancer drug target

Feb 06, 2012

Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

Recommended for you

Taking the guesswork out of cancer therapy

38 minutes ago

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test ...

Brain tumour cells found circulating in blood

1 hour ago

(Medical Xpress)—German scientists have discovered rogue brain tumour cells in patient blood samples, challenging the idea that this type of cancer doesn't generally spread beyond the brain.

International charge on new radiation treatment for cancer

2 hours ago

(Medical Xpress)—Imagine a targeted radiation therapy for cancer that could pinpoint and blast away tumors more effectively than traditional methods, with fewer side effects and less damage to surrounding tissues and organs.

Computer model reveals cancer's energy source

3 hours ago

(Medical Xpress)—A computer model study reveals – for the first time – details of an energy-creating process vital and unique to cancer cells. The research holds promise for new interventions and for ...

User comments